Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Values First Advisors Inc.

Values First Advisors Inc. cut its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 16.8% during the 4th quarter, Holdings Channel reports. The firm owned 7,951 shares of the medical research company’s stock after selling 1,607 shares during the period. Values First Advisors Inc.’s holdings in Exact Sciences were worth $447,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Chicago Partners Investment Group LLC boosted its stake in Exact Sciences by 1.7% during the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock valued at $651,000 after buying an additional 158 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in Exact Sciences by 3.2% in the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after acquiring an additional 264 shares during the last quarter. Huntington National Bank boosted its position in shares of Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Exact Sciences by 6.1% in the 3rd quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after purchasing an additional 371 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its holdings in shares of Exact Sciences by 1.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock worth $1,952,000 after purchasing an additional 402 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Trading Down 1.4 %

NASDAQ EXAS opened at $50.34 on Thursday. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The firm’s fifty day simple moving average is $56.66 and its 200-day simple moving average is $60.13. The company has a market capitalization of $9.32 billion, a PE ratio of -43.03 and a beta of 1.24.

Analyst Ratings Changes

A number of brokerages recently weighed in on EXAS. Jefferies Financial Group raised their target price on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Sanford C. Bernstein raised their price objective on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Citigroup cut their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Bank of America decreased their price target on Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Benchmark restated a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, Exact Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $72.76.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.